Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
| Autor: | Shawn Kile, Dan Redline, Tammy Donnel, Jaideep Sohi, Carol Parise, Kimberley Rose, Kenneth O. Johnson, Alan D. Czeszynski, Andrea Hankins, William Au, Tracy Yarbrough |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Amyloid Central nervous system Retina 03 medical and health sciences 0302 clinical medicine medicine Humans Cognitive Dysfunction Cognitive impairment Aged Amyloid beta-Peptides Aniline Compounds biology business.industry General Neuroscience Brain Immunoglobulins Intravenous Psychiatry and Mental health Clinical Psychology 030104 developmental biology medicine.anatomical_structure Positron-Emission Tomography Immunology biology.protein Ethylene Glycols Female Geriatrics and Gerontology Antibody business 030217 neurology & neurosurgery After treatment |
| Zdroj: | American journal of Alzheimer's disease and other dementias. 35 |
| ISSN: | 1938-2731 |
| Popis: | Objective:To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS).Methods:Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed.Results:Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye.Conclusions:A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|